• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2023

View Archived Issues
Close-up of nasal drug spraying

Nasal anti-CD3 antibody improves Alzheimer’s disease in mice

Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic of this neurodegenerative disorder. “We have done many basic studies in the laboratory on microglia. Microglia activation occurs in many neurologic diseases. One of them is multiple sclerosis (MS). And it also occurs in AD,” senior author Howard Weiner told BioWorld. Read More

BC-3448 CD3-based bispecific antibody shows robust antitumor effect

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with documented efficacy in non-small-cell lung cancer. However, in most cases, patients develop resistance to this treatment by mechanisms that are not clear in half of the cases. Researchers from Shanghai Pulmonary Hospital presented data on BC-3448, a bispecific antibody targeting EGFR and CD3 aimed to recruit T cells to tumors with high EGFR expression leading to T cell-driven tumor cell killing. The compound presents a stronger binding affinity for EGFR than for CD3 to avoid the development of cytokine release syndrome, which is a safety issue common in CD3-based bispecific antibodies. Read More
Radiotherapy of cancer

RAYZ-8009, a radiopharmaceutical therapy agent with efficacy in models of GPC3-positive HCC

It has been previously demonstrated that glypican-3 (GPC3) is differentially expressed in hepatocellular carcinomas (HCC), making it a promising target for radiopharmaceutical therapy to treat HCC. At the ongoing meeting of the European Association of Nuclear Medicine in Vienna, researchers from Rayzebio Inc. and Peptidream Inc. presented the preclinical characterization of a novel proprietary peptide binder of GPC3, RAYZ-8009. Read More
3d illustration of ovarian cancer

Aprea reports new preclinical data on WEE1 inhibitor

Aprea Therapeutics Inc. has released updated preclinical data supporting potential safety and... Read More

New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful... Read More

Holiday notice

In accordance with the publishing schedule, BioWorld Science was not published on Monday, Sept. 11, 2023. Read More
Mast cell

Hoth seeks pre-IND meeting with FDA for HT-KIT

Hoth Therapeutics Inc. has submitted a request for a pre-IND meeting to the FDA to discuss the... Read More

Lucy Therapeutics prepares and tests adenosine receptor agonists for Rett syndrome

Researchers at Lucy Therapeutics Inc. have identified new adenosine receptor agonists... Read More
Dermatology-psoriasis-eczema-pic

Novel AhR agonist with enhanced antipsoriatic activity

Aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that maintains skin homeostasis in healthy skin and is expressed in keratinocytes, fibroblasts, mastocytes and melanocytes. In inflammatory skin disorders such as psoriasis, AhR deficit leads to marked skin inflammation, abnormal barrier function and increased cytokine release. Researchers from Sichuan University have reported the discovery and optimization of a new series of 2-thioxoimidazolidin-4-one derivatives acting as AhR agonists that led to the identification of [I] as the lead compound, which showed an EC50 value of 0.015 µM against AhR. Read More

HC-2210, a nitrofuran compound with activity against M. tuberculosis and M. abscessus

Researchers from Michigan State University and Tarn Biosciences Inc. have published their work on the discovery and preclinical evaluation of novel antimycobacterial nitro-containing compounds. Read More

Pivalent Therapeutics Inc. patents PI3Kα inhibitors

Pivalent Therapeutics Inc. has reported the development of phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors. Read More
Hepatitis-B-virus.png

Precision Biosciences outlines pipeline progress

Precision Biosciences Inc. uses its proprietary Arcus platform to develop in vivo gene editing therapies and has outlined new data from its wholly owned and partnered pipeline. Read More

Duke Street Bio reports PARP-1 inhibitors for treatment of cancer

A Duke Street Bio Ltd. patent details new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer. Read More

Accent Therapeutics describes DHX9 inhibitors for cancer

ATP-dependent RNA helicase A (DHX9) inhibitors have been reported in an Accent Therapeutics Inc. patent as potentially useful for the treatment of cancer. Read More
Pipet, test tubes, chemical structure

Eikon Therapeutics advances preclinical pipeline

Eikon Therapeutics Inc. has received IND clearance from the FDA to initiate phase I studies with IMP-1734, a highly selective poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor developed in partnership with Impact Therapeutics Inc. Read More

Other news to note for Sept. 12, 2023

Additional early-stage research and drug discovery news in brief, from: Blue Earth, Sling. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe